From Financialpost · · 1m
Ipsen Boosts Sales Growth and Upgrades 2026 Guidance
Ipsen reports 24.6% year-to-date sales growth and raises full-year 2026 financial targets.
In brief
Ipsen reports 24.6% year-to-date sales growth and raises full-year 2026 financial targets. Ipsen achieved 24.6% year-to-date sales growth and upgraded its 2026 sales and margin guidance to 23.0% and 39.0%. Originally reported by Financialpost.
Ipsen Sales Growth
Ipsen reported 24.6% year-to-date sales growth at CER, up from 23.0% in 2025.
“Year-to-date total sales growth of 24.6% at CER, or 23.0% as reported”
Upgraded 2026 Guidance
Ipsen raised full-year 2026 sales growth guidance to 23.0% at CER and core operating margin to 39.0%.
“Total sales growth around 23.0% at CER (prior guidance: greater than 20.0% at CER); core operating margin around 39.0% of total sales (prior guidance: greater than 37.0%)”
Pipeline Strengthens
Ipsen's late-stage pipeline includes oncology, rare disease and neuroscience assets with blockbuster potential.
“Multiple late-stage pipeline assets with blockbuster potential in Oncology, Rare Disease and Neuroscience”
CEO Statement
CEO David Loew attributes growth to core portfolio strength and Somatuline sales expansion.
“Our outstanding performance in the first nine months of 2026 is driven by the strength of our core portfolio and continued growth of Somatuline”
Key Pipeline Assets
Ipsen's pipeline includes Dysport for migraine, Iqirvo for primary biliary cholangitis and navtemadlin for myelofibrosis.
“We have the potential to address substantial unmet needs and expand our reach to new patient populations through Dysport in episodic and chronic migraine and, through Iqirvo with a potential label update in primary biliary cholangitis”
Acquisitions Boost Pipeline
Ipsen acquired Memo Therapeutics and Kartos Therapeutics to add potravitug and navtemadlin to its pipeline.
“Ipsen completed the acquisitions of Memo Therapeutics and Kartos Therapeutics, adding potravitug, a late-stage anti-BK polyomavirus monoclonal antibody, and navtemadlin, a Phase III MDM2 inhibitor for myelofibrosis”
The headline
Ipsen achieved 24.6% year-to-date sales growth and upgraded its 2026 sales and margin guidance to 23.0% and 39.0%.
